D116 Unit 3 Study Guide

Student Name
Western Governors University
D116 Advanced Pharmacology for the Advanced Practice Nurse
Prof. Name
Date
Unit 3 Study Guide
Location and Function of Cholinergic Receptor Subtypes
Cholinergic receptors are divided into two main classes: muscarinic and nicotinic receptors. Each subtype is distributed in specific anatomical regions and produces unique physiological effects by mediating acetylcholine’s action within the central and peripheral nervous systems. Recognizing where these receptors are located and their functions is essential for predicting both therapeutic outcomes and side effects when using cholinergic or anticholinergic drugs.
| Receptor Subtype | Primary Location | Physiological Response |
|---|---|---|
| Muscarinic (M1–M5) | Central nervous system, heart, smooth muscle, glands | Controls heart rate, gland secretion, and smooth muscle contraction |
| Nicotinic (Nm) | Neuromuscular junction | Facilitates skeletal muscle contraction |
| Nicotinic (Nn) | Autonomic ganglia, adrenal medulla | Activates autonomic nervous system responses |
Pramipexole: Drug Classification, Mechanism, and Clinical Applications
Pramipexole, marketed as Mirapex, is classified as a nonergot dopamine receptor agonist. It plays a significant role in treating neurological conditions such as Parkinson’s disease (PD) and restless legs syndrome (RLS).
Mechanism of Action
Pramipexole works by selectively stimulating dopamine D2 and D3 receptors, with a predominant effect on the D2 subtype. This stimulation mimics the function of dopamine in the basal ganglia, helping to offset the dopamine deficiency that characterizes Parkinson’s disease.
Clinical Uses
For patients in the early stages of Parkinson’s, pramipexole may be prescribed as the sole therapy. In later stages, it is often used alongside levodopa to manage motor fluctuations more effectively. The drug is also FDA-approved for treating moderate to severe restless legs syndrome, where it helps reduce symptoms.
Role of Ergot Derivatives in Parkinson’s Disease Treatment
Historically, ergot-derived dopamine agonists like bromocriptine and cabergoline were common in Parkinson’s disease management. However, their use has declined sharply due to safety concerns.
Limitations and Risks
While these drugs do stimulate dopamine receptors, they also block serotonergic and α-adrenergic receptors. This broad receptor activity raises the risk of serious adverse effects such as cardiac valve disease and fibrotic tissue complications. Because of these safety issues, ergot derivatives are now rarely used in modern Parkinson’s treatment protocols.
Optimal Pharmacologic Therapy for Restless Legs Syndrome
Pramipexole is the preferred first-line medication for moderate to severe restless legs syndrome. Its dopaminergic properties effectively alleviate the uncomfortable sensations and the urge to move, especially during rest.
Gabapentin is another widely used alternative, particularly beneficial for patients who also experience neuropathic pain or sleep disorders. This drug operates through different mechanisms, offering symptom relief in cases where dopaminergic therapy is insufficient or contraindicated.
Preventive Treatment for Cluster Headaches: Drug Classes and Rationales
Preventing cluster headaches focuses on minimizing the number and severity of attacks. The medications used for prophylaxis belong to several classes, each with specific clinical justifications:
| Drug Class | Examples | Clinical Rationale |
|---|---|---|
| Calcium Channel Blockers | Verapamil | Primary first-line agent for prevention |
| Glucocorticoids | Prednisone, Dexamethasone | Used short-term to suppress inflammation |
| Mood Stabilizers | Lithium | Particularly effective in chronic cluster headache |
Distinguishing Preventive and Abortive Migraine Treatments
Migraine management involves two approaches: abortive therapy to stop active attacks and preventive therapy to reduce their frequency and severity.
Abortive Therapy
This treatment aims to relieve symptoms during a migraine episode, including headache pain, nausea, and vomiting. It includes:
- Nonspecific agents: Nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics
- Migraine-specific agents: Triptans (which act as serotonin 5-HT1B/1D receptor agonists) and ergot alkaloids
Preventive Therapy
Preventive medications are taken regularly to reduce migraine occurrence over time. Examples include:
| Drug Class | Examples |
|---|---|
| Beta blockers | Propranolol |
| Tricyclic antidepressants | Amitriptyline |
| CGRP receptor antagonists | Erenumab |
| Antiepileptic drugs | Divalproex |
Goals of Pharmacologic Treatment in Schizophrenia
The primary aim of drug therapy in schizophrenia is to prevent relapse and stabilize symptoms. Long-term maintenance treatment with antipsychotics significantly lowers the risk of acute psychotic episodes. However, these medications may not fully stop cognitive or functional decline that can occur over time.
Medication Follow-Up Plan in Depression Management
Ongoing monitoring is vital during depression treatment to evaluate therapeutic response, side effects, and patient safety, including vigilance for suicidal thoughts.
Medication Evaluation Timeline
Typically, antidepressants require 4 to 8 weeks of therapy before assessing their effectiveness. Treatment begins with low doses, gradually increasing to reduce adverse effects.
Adjustments If Initial Treatment Fails
Options include:
- Increasing the dose
- Switching to another medication in the same drug class
- Changing to a different antidepressant class
- Adding an adjunct medication, such as an atypical antidepressant
Lithium Toxicity: Adverse Effects and Therapeutic Levels
Lithium has a narrow therapeutic window, necessitating careful blood level monitoring.
| Serum Lithium Level (mEq/L) | Clinical Effects |
|---|---|
| < 1.5 | Therapeutic range; mild tremor and gastrointestinal upset possible |
| 1.5 – 2.5 | Moderate toxicity; symptoms include confusion and worsening tremor |
| > 2.5 | Severe toxicity; may cause seizures, coma, or death |
The therapeutic range typically lies between 0.6 and 1.2 mEq/L, depending on the clinical condition treated.
Mechanism and Side Effects of Atypical Antidepressants
Atypical antidepressants work through diverse mechanisms such as inhibiting dopamine and norepinephrine reuptake or modulating serotonin receptors.
Common Adverse Reactions
Side effects often reported include agitation, headache, dry mouth, constipation, gastrointestinal upset, weight loss, dizziness, tremor, insomnia, blurred vision, and rapid heartbeat. The specific profile may vary by individual medication.
Differences Between Reversible and Irreversible Cholinesterase Inhibitors
Cholinesterase inhibitors function by blocking the enzyme acetylcholinesterase, which increases acetylcholine levels and enhances cholinergic signaling.
| Type | Duration of Action | Common Uses |
|---|---|---|
| Reversible inhibitors | Moderate | Used for myasthenia gravis, Alzheimer’s disease, glaucoma, Parkinson’s dementia |
| Irreversible inhibitors | Long-lasting | Limited clinical use; some applied in glaucoma treatment |
Reversible inhibitors are generally preferred due to their safer and more predictable effects.
Patient Education and Precautions for Clonidine Patches
Clonidine is a centrally acting α2-adrenergic agonist prescribed for hypertension, severe pain, and attention-deficit hyperactivity disorder (ADHD).
Key Patient Instructions
Patients should be advised to:
- Regularly monitor and document their blood pressure
- Apply patches only to clean, hairless, and intact skin on the upper arm or torso
- Replace the patch every seven days
- Avoid sudden discontinuation to prevent rebound hypertension
References
American Psychiatric Association. (2022). Practice guideline for the treatment of patients with schizophrenia. APA Publishing.
Katzung, B. G., Vanderah, T. W., & Trevor, A. J. (2021). Basic & clinical pharmacology (15th ed.). McGraw-Hill Education.
D116 Unit 3 Study Guide
Stahl, S. M. (2021). Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press.
UpToDate. (2024). Pharmacologic management of Parkinson disease and migraine disorders. Wolters Kluwer.